The use of ICIs in treating triple-negative breast cancer (TNBC) remains ineffective due to multiple factors, for instance, the presence of Transforming Growth Factor (TGF-β), which is known to reprogram the tumor microenvironment in Triple Negative Breast Cancer. This evidence concerns the gene TGFB1 and triple-negative breast carcinoma.